Veeva Systems Company Profile (NYSE:VEEV)

Veeva Systems trades on the New York Stock Exchange (NYSE) under the ticker symbol "VEEV."

Veeva Systems Inc. (NYSE:VEEV) issued its quarterly earnings results on Thursday, August, 24th. The company reported $0.23 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.20 by $0.03. The company earned $166.59 million during the quarter, compared to the consensus estimate of $164.26 million. Veeva Systems had a net margin of 18.98% and a return on equity of 12.77%. Veeva Systems's revenue was up 26.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.15 EPS. View Veeva Systems' Earnings History.

Veeva Systems is scheduled to release their next quarterly earnings announcement on Tuesday, November, 28th 2017. View Earnings Estimates for Veeva Systems.

Veeva Systems issued an update on its FY18 earnings guidance on Thursday, August, 24th. The company provided earnings per share (EPS) guidance of $0.86-0.87 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.83. The company issued revenue guidance of $672-674 million, compared to the consensus revenue estimate of $669.86 million.Veeva Systems also updated its Q3 guidance to $0.21-0.22 EPS.

11 brokers have issued 1-year target prices for Veeva Systems' shares. Their predictions range from $47.00 to $70.00. On average, they expect Veeva Systems' stock price to reach $65.82 in the next year. View Analyst Ratings for Veeva Systems.

Here are some recent quotes from research analysts about Veeva Systems stock:

• 1. According to Zacks Investment Research, "Veeva Systems outperformed the broader industry on a year-to-date basis, on the back of its splendid earnings surprise history. Notably, the company has delivered positive earnings surprise in all the past four quarters. Further, the company remains on track with its commercial cloud platform, which registered multiple contracts around the world. Veeva has also many core CRM projects on track with large pharma companies around the globe. The company has strengthened the recurring part of its revenue mix by marking significant growth in subscription revenues in the last quarter. Moreover, the new launches at the Veeva Vault and the Veeva Coomercial Cloud platforms are encouraging. However, intensifying competition, high operating expenses and a saturating lifesciences market are key concerns." (10/11/2017)
• 2. KeyCorp analysts commented, "We are raising revenue estimates by $5M in F2018 and nearly $10M in F2019 based on the assumption that (1) Vault growth remains at or above 40%, and (2) Commercial Cloud plus services can sustain growth at or above 10% y/y." (8/25/2017)
• 3. Bank of America Corp analysts commented, "greater confidence" that the company is in the early stages of a multi-billion-dollar revenue opportunity with Vault. In fact, the analyst sees Veeva's Vault opportunity in both the large pharmaceutical installed base (which presents an additional $400 to $500 million revenue opportunity) along with life sciences start-ups, which was previously un-addressed.Sills also noted that commercial could also sustain a "health" mid-teens growth rate due to: 1) cross selling of PromoMats, 2) cross-selling CRM add-ons, 3) expansion in the already existing installed base and 4) new customer wins intentionally, especially in Japan and Europe. Finally, the analyst explained that his new $70 price target represents a 42x EV/FCF multiple on his 2018 estimates which is "reasonable" relative to the analyst's estimated three-year FCF compounded annual growth rate of 30 percent, which is likely to be proven conservative. At time of publication, shares of Veeva were up 6.33 percent at $65.65." (5/26/2017)
• 4. Stifel Nicolaus analysts commented, "On February 28th, after the market close, Veeva delivered F4Q17 financial results that came in ahead of consensus across all key metrics. Highlights in the quarter included the two largest Vault deals in the company's history and a top-20 pharma selecting Veeva for a standardization of Veeva CRM across its domestic Japanese operations. Veeva closed the year with 517 total customers (+117 y/y), including 145 clinical customers (+70% y/y) and 100+ quality customers (+80% y/y), a solid improvement in all key functions of pharma organizations. Veeva continues to display solid execution across all areas of the business, evidenced by 19% Commercial Cloud growth and 120% Vault growth in the fiscal year (including the Zinc Ahead acquisition), and its best in class 127% subscription services revenue retention rate. We believe Veeva is tracking ahead of its $1bn revenue run rate target for 2020 within Life Sciences and see additional opportunities for revenue growth through the expansion of certain Vault modules to areas outside of the industry. We maintain our Buy rating and we are raising our price target from $48 to $50 on shares of VEEV." (3/1/2017)
• 5. Needham & Company LLC analysts commented, " VEEV reported sustained business momentum in 4Q with revenue, EPS, and billings easily beating estimates as Vault expands sales impact to new modules and across verticals. New customer metrics accelerated in FY17 over FY16 led by Vault (115 adds vs. 84 in FY16) but CRM also had much higher new customer adds (47 vs. 16 in FY16). VEEV's Vault momentum that extended in 4Q included its two largest deals ever, two large Vault Quality wins with two top 30 global chemical companies, and its first Vault RIM deals with top 20 Pharma customers. We believe these new Vault successes yield incremental confidence that VEEV can sustain a 20% + growth profile for the next two or three years at a minimum and does not include any assumptions for EDC, which can add upside to our growth thesis if successful with initial 2Q18 trials." (3/1/2017)

Some companies that are related to Veeva Systems include athenahealth (ATHN), Cotiviti Holdings (COTV), HealthEquity (HQY), Allscripts Healthcare Solutions (MDRX), Omnicell (OMCL), Evolent Health (EVH), Emis Group Plc (EMIS), Castlight Health, inc. (CSLT), NantHealth (NH), Tabula Rasa Healthcare (TRHC), Craneware plc (CRW), Simulations Plus (SLP), Fluidigm Corporation (FLDM), Medical Transcription Billing, Corp. (MTBC), Constellation Healthcare Tech (CHT) and Press Ganey Holdings (PGND).

Veeva Systems' management team includes the folowing people:

• Gordon Ritter, Independent Chairman of the Board
• Matthew J. Wallach, President
• Peter P. Gassner, Chief Executive Officer, Director
• Timothy S. Cabral, Chief Financial Officer
• Alan V. Mateo, Executive Vice President of Sales
• Jonathan W. Faddis, Senior Vice President, General Counsel, Corporate Secretary
• Frederic Lequient, Senior Vice President - Global Customer Services
• E. Nitsa Zuppas, Chief Marketing Officer
• Mark T. Carges, Director
• Timothy C. Barabe, Independent Director

Shares of Veeva Systems can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Veeva Systems stock can currently be purchased for approximately $58.65.